Advances in the Management of Hemophilia and Bleeding Disorders: Achievements and Perspectives
Antonio Coppola,Massimo Franchini
DOI: https://doi.org/10.1055/s-0044-1800835
2024-12-07
Seminars in Thrombosis and Hemostasis
Abstract:These are exciting times for the hemophilia community: over the last decade the management and lives of patients are being actually transformed by the introduction in the clinical practice of innovative products, also providing newer therapeutic approaches additional to conventional replacement of the deficient factors (i.e., nonreplacement products and gene therapy).[1] Innovative approaches, including the first introduced nonreplacement product, emicizumab, are being also experienced and investigated in the treatment of bleeding disorders other than congenital hemophilia. For these reasons, this latest Issue of Seminars in Thrombosis and Hemostasis is dedicated not only to the current advances and perspectives in the management of hemophilia A (HA) and B (HB), but also in other challenging conditions with unmet treatment needs, like acquired hemophilia, von Willebrand disease (VWD), and hereditary hemorrhagic telangiectasia (HHT). Introducing this evolving scenario, the first of the 11 chapters of the current issue reviews the outstanding progress of therapeutic products for hemophilia over the last half a century, from the plasma-derived replacement products, through the era of recombinant technologies—standard half-life and extended half-life (EHL) factor concentrates—up to the recent nonreplacement approaches and the first licensed gene therapy products.[2] In parallel, the management of persons with hemophilia (PWH) has also evolved: personalized prophylaxis regimens became the standard of care and the bar of therapeutic target continuously raised from the prevention of bleeding to the avoidance of joint damage and the best possible quality of life. Currently, the unimaginable perspective of "health equity,"[3] i.e., leading a healthy life without physical and psychological restrictions, similar to nonaffected peers, is becoming achievable, thanks to therapeutic products able to virtually normalize hemostasis.[2] The achievements, open issues, and perspectives of the different therapeutic approaches currently available for hemophilia are expanded in the subsequent chapters. Regarding replacement products for HA, the literature data showing the benefits of EHL Factor (F) VIII products in improving prophylaxis feasibility, individualization, and outcomes are summarized by Mancuso.[4] These modified FVIII EHL molecules (by Fc-fusion or pegylation) introduced in the last decade have enabled tailored prophylaxis regimens according to the specific protection and convenience needs, with reduced infusion frequency and/or higher FVIII trough levels. A remarkable improvement of pharmacokinetic properties is shown by the new-generation molecule efanesoctocog alfa, able to overcome the binding to the endogenous von Willebrand factor (VWF), at variance with previous products, and to provide FVIII levels and hemostatic protection in the nonhemophilia range over much longer time periods. Mancuso also discusses these recent achievements,[4] claiming the renaissance of FVIII replacement treatment[5] against the change of paradigm introduced by emicizumab, the first nonreplacement agent for prophylaxis in hemophilia. Indeed, this FVIII mimetic, which revolutionized the management of PWH A with inhibitors, making possible a highly effective prophylaxis of bleeding, provided an alternative even for those without inhibitors, with a lower treatment burden thanks to the long-interval subcutaneous administration. The advance and potential implications of nonreplacement products are discussed by Jiménez-Yuste in the next chapter.[6] Beyond emicizumab, newer FVIII mimetics (mim8, NXT007) and several rebalancing agents, enhancing thrombin generation by inhibiting the natural anticoagulant pathways, are in different phase of clinical trials or being introduced in the market. The latter, including two antitissue factor pathway inhibitor monoclonal antibodies (concizumab and marstacimab), an antithrombin small interfering RNA (fitusiran) and agents targeting the activated protein C (like serpinPC) or protein S, are effective in both HA and HB, regardless of inhibitors. Therefore, these products provide a prophylactic approach particularly useful for the challenging management of patients with HB and inhibitors.[7] Nonreplacement products, unlike the intravenous peak-and-trough hemostatic replacement by factor concentrates, generate stable thrombin levels by subcutaneous administration, shifting severe hemophilia toward a milder phenotype. These clear advantages should be considered together with still open issues, including the potential thrombotic risk requiring mitigation measures (particularly the optimization of combined replacement/bypassing treatment for surgery or intercurrent bleeding), the development of anti-drug antibodies (ADA) and the absence of standardized laboratory assessments.[6] Three chapters then deal with the most innovativ -Abstract Truncated-
peripheral vascular disease,hematology